Loading insider details...
Beta
Latest Form 4 (Jun 26, 2026): Grant/Award of 19,000 CTNM shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 26, 2026 | Contineum Therapeutics, Inc. (CTNM) | Grant/Award | 19,000 | n/a |
| Apr 28, 2026 | Arcellx, Inc. (ACLX) | Disposition to Issuer | 36,806 | n/a |
| Jun 26, 2025 | Contineum Therapeutics, Inc. (CTNM) | Grant/Award | 14,750 | n/a |
| May 30, 2025 | Arcellx, Inc. (ACLX) | Grant/Award | 9,174 | n/a |
| Jun 6, 2024 | Arcellx, Inc. (ACLX) | Grant/Award | 8,011 | n/a |
| May 29, 2024 | Contineum Therapeutics, Inc. (CTNM) | Grant/Award | 3,700 | n/a |
| May 3, 2024 | Revance Therapeutics, Inc. (RVNC) | Grant/Award | 15,000 | n/a |
| Apr 18, 2024 | Arcellx, Inc. (ACLX) | Exercise/Conversion | 9,402 | $71.5K |
| Mar 18, 2024 | Arcellx, Inc. (ACLX) | Exercise/Conversion | 9,000 | $68.5K |
| Jun 16, 2023 | Arcellx, Inc. (ACLX) | Grant/Award | 11,459 | n/a |